Phase 2 Data for Selective Oral JAK3 Inhibitor VX-509 Show Significant...
Phase 2 Data for Selective Oral JAK3 Inhibitor VX-509 Show Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis Yahoo/BusinessWire
View ArticleOutlooks for Pfizer, Arena and Onyx Following Busy May
Outlooks for Pfizer, Arena and Onyx Following Busy May TheStreet.com
View ArticleTaxpayer Funds, A Pfizer Drug And Big Profits
Taxpayer Funds, A Pfizer Drug And Big Profits Pharmalot
View Article
More Pages to Explore .....